Drug Target Review

Created by the knowledgeable team at European Pharmaceutical Review, Drug Target Review serves as a key platform for the drug discovery sector. It highlights the newest research findings, funding initiatives, and innovative technologies shaping the industry.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#697508

United States

#528886

Health/Health Conditions and Concerns

#1483

Traffic sources

Monthly visitors

Articles

What SLAS 2025 really told us about drug discovery

1 week ago | drugtargetreview.com | Carrie Haslam

articlePosted: 30 May 2025 | Carrie Haslam | Forget the buzzwords – SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems. Drug Target Review had the pleasure of attending SLAS Europe 2025 in Hamburg and what we saw was no mere showcase of cutting-edge tools, but a clear snapshot of where drug discovery is heading.
Key PKD findings could accelerate development of new treatments - Drug Target Review

1 month ago | drugtargetreview.com

Explore the latest research on polycystic kidney disease and its implications in understanding the role of the worm.
New research offers hope for high-grade glioma treatment - Drug Target Review

2 months ago | drugtargetreview.com

Explore the latest advancements in glioma treatment, focusing on avapritinib's impact on high-grade glioma patients.
CeSPIACE: New peptide drug blocks COVID-19 variants

2 months ago | drugtargetreview.com | Carrie Haslam

Posted: 20 March 2025 | Drug Target Review | Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
CRANE Technology: Hope for ALS and inflammatory diseases

2 months ago | drugtargetreview.com

Explore CRANE technology, an innovative platform revolutionising the treatment of inflammatory diseases with Treg-based therapies.
First AI-designed drug, Rentosertib, officially named by USAN

2 months ago | drugtargetreview.com | Carrie Haslam

Posted: 14 March 2025 | Drug Target Review | Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
Diabetes drug found to protect heart during cancer treatment

2 months ago | drugtargetreview.com | Carrie Haslam

Posted: 13 March 2025 | Drug Target Review | A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals. Protecting the heart during cancer treatmentCancer treatments, particularly chemotherapy, often lead to severe cardiovascular complications that substantially impact patient health and quality of life.
Scientists turn superbug MRSA into treatable infection

2 months ago | drugtargetreview.com | Carrie Haslam

Posted: 12 March 2025 | Drug Target Review | Researchers have discovered a breakthrough method to silence MRSA’s drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs. A study from the Nanjing University School of Life Sciences has revealed a promising new strategy for combating antibiotic-resistant bacterial infections.
Bacterial ‘jumping genes’ found to control chromosome ends

2 months ago | drugtargetreview.com | Carrie Haslam

Posted: 10 March 2025 | Drug Target Review | Cornell researchers have discovered how transposons, or ‘jumping genes,’ insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
Google’s AI co-scientist accelerates drug development

Mar 7, 2025 | drugtargetreview.com | Carrie Haslam

Posted: 7 March 2025 | Drug Target Review | Google has introduced an AI-powered ‘co-scientist’ designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets. Google’s newly introduced AI co-scientist, powered by Gemini 2.0, is designed to assist researchers by generating hypotheses, designing experiments, and analysing complex datasets.